Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance

2002 ◽  
Vol 17 (12) ◽  
pp. 1291-1298 ◽  
Author(s):  
JUN-ICHI TOGAWA ◽  
HAJIME NAGASE ◽  
KATSUAKI TANAKA ◽  
MASAHIKO INAMORI ◽  
ATSUSHI NAKAJIMA ◽  
...  
2005 ◽  
Vol 3 (2) ◽  
pp. 63-73 ◽  
Author(s):  
C. G. Vinderola ◽  
J. Duarte ◽  
D. Thangavel ◽  
G. Perdigon ◽  
E. Farnworth ◽  
...  

Kefir is a fermented milk (drink) produced by the action of lactic acid bacteria, yeasts and acetic acid bacteria. We recently reported a comparative study on the effect of kefir containing viable or non-viable bacteria by studying their modulatory activity on the intestinal immune response. A functional dose was established in a murine model and the pattern of regulatory and pro-inflammatory cytokines induced was also studied. The existence of a common mucosal immune system implies that the immune cells stimulated in one mucosal tissue can spread and relocate through various mucosal sites. The aim of this work was to determine the effect of an oral administration of kefir on the duration of the intestinal mucosa immune response and the modulatory activity in distal mucosal sites, specifically in the peritoneal and pulmonary macrophages and in the bronchial tissue. BALB/c mice were fed with kefir or pasteurized kefir at doses previously determined as functional for intestinal mucosa immunomodulation. Kefir feeding was stopped and the number of IgA, IgG, IL-4, IL-6, IL-10, IIFNγ and TNFα producing cells was determined in the lamina propria of small intestine immediately, and after 2 and 7 days of kefir withdrawal. IgA producing cells were also measured in the bronchial tissue of lungs immediately and 2 and 7 days after kefir withdrawal. Phagocytic activity of peritoneal and pulmonary macrophages was also determined. The oral administration of kefir or pasteurized kefir increased the number of IgA+ cells not only in the gut lamina propria, but also in the bronchial tissue, supporting the concept of local antibody secretion after remote-site stimulation in the intestinal tract. Both peritoneal and pulmonary macrophages were activated by kefir or pasteurized kefir feeding. Peritoneal macrophages were stimulated faster than pulmonary macrophages (for kefir). The enhanced phagocytic activity achieved by kefir or pasteurized kefir lasted longer for the peritoneal than for the pulmonary macrophages. Due to the increased bronchial IgA and phagocytic activity of pulmonary macrophages after kefir feeding observed in this study, the oral administration of kefir could act as a natural adjuvant for enhancing the specific immune response against respiratory pathogens. The parameters studied returned to control values within a week of cessation of kefir administration. This would suggest that there is a low risk of overstimulating the gut mucosal immune system during periodic consumption of kefir.


Reproduction ◽  
2021 ◽  
Author(s):  
María Silvia Ventimiglia ◽  
Natalin Jimena Valeff ◽  
Marlon pozo Albán ◽  
Juan Manuel Paturlanne ◽  
Lorena Juriol ◽  
...  

Preterm birth (PTB), defined as birth occurring before 37 weeks of pregnancy, affects 5-18% of pregnancies and is the leading cause of neonatal morbidity and mortality worldwide. Although PTB is considered a syndrome, infection-induced inflammation accounts up to 50% of all cases. Despite the effort to reduce the incidence of PTB, it continues rising worldwide and current approaches for preventing or treating PTB are largely unsatisfactory. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. It is well known that probiotics can modulate the host immune system exerting a potent anti-inflammatory activity. The main aim of this work was to evaluate the capacity of the probiotic Lactobacillus kefiri (Lk48) to prevent preterm birth in mice. C57BL/6 female mice were treated with Lk48 or vehicle a week before and during pregnancy and were challenged with LPS (10 µg), a dose known to induce 100% of PTB, on gestational day 16. Percentages of PTB as well as stillbirth were evaluated. We observed that oral administration of Lk48 significantly reduced the occurrence of LPS-induced PTB and stillbirth as well as improved post-natal development. This protective effect was associated with a reduction in leucocyte infiltration and reduced inflammation-induced damage in reproductive tissue. Besides, Lk48 treatment also modulated the diversity of vaginal microbiota. Our results demonstrated that prophylactic consumption of probiotic Lactobacillus kefiri prevented LPS-induced PTB and still birth in mice and open new avenues for exploring novel and promising strategies for preventing PTB in humans.


2002 ◽  
Vol 283 (1) ◽  
pp. G187-G195 ◽  
Author(s):  
Jun-Ichi Togawa ◽  
Hajime Nagase ◽  
Katsuaki Tanaka ◽  
Masahiko Inamori ◽  
Tadashi Umezawa ◽  
...  

Natural immunomodulator lactoferrin is known to exert an anti-inflammatory effect. However, there have been no studies that examine the mode of action of lactoferrin in reducing intestinal damage. We investigated the effect of lactoferrin on a trinitrobenzenesulfonic acid (TNBS)-induced colitis model in rats. Bovine lactoferrin was given once daily through gavage, starting 3 days before (preventive mode) or just after TNBS administration (treatment mode) until death. The distal colon was removed to be examined. Colitis was attenuated by lactoferrin via both modes in a dose-dependent manner, as reflected by improvement in macroscopic and histological scores and myeloperoxidase activity. Lactoferrin caused significant induction of the anti-inflammatory cytokines interleukin (IL)-4 and IL-10, significant reductions in the proinflammatory cytokines tumor necrosis factor-α and IL-1β, and downregulation of the nuclear factor-κB pathway. We concluded that lactoferrin exerts a protective effect against colitis in rats via modulation of the immune system and correction of cytokine imbalance. Lactoferrin has potential as a new therapeutic agent for inflammatory bowel disease.


2015 ◽  
Vol 34 ◽  
pp. S34
Author(s):  
K.A. Tanaka ◽  
T. Shibakusa ◽  
S. Kurihara

Sign in / Sign up

Export Citation Format

Share Document